jcm-logo

Journal Browser

Journal Browser

Retinal Diseases: Emerging Therapies and Vision Rehabilitation

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Ophthalmology".

Deadline for manuscript submissions: 15 April 2026 | Viewed by 522

Special Issue Editor


E-Mail Website
Guest Editor
Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
Interests: vitreoretinal disorder; vitrectomy; digital assisted vitrectomy; intraoperative optical coherence tomography; diabetic retinopathy; epiretinal membrane

Special Issue Information

Dear Colleagues,

Retinal diseases are among the leading causes of visual impairment and blindness worldwide, affecting vast numbers of people and posing a serious public health challenge. Recent advances in biomedical research have led to the development of diverse novel therapeutic strategies, including gene therapy, stem cell–based treatments, neuroprotective agents, innovative pharmacological approaches, and surgical interventions. At the same time, efforts have been made to refine and optimize the application of existing treatments to address the limitations and challenges of newly developed therapies. Furthermore, for cases in which these interventions alone cannot restore sufficient visual function, vision rehabilitation—integrating advanced optical devices, digital technologies, and personalized training programs—has played a vital role in improving patients’ functional vision and quality of life (QoL).

This Special Issue, “Retinal Diseases: Emerging Therapies and Vision Rehabilitation,” aims to share knowledge that will enhance the understanding and application of best clinical practices, ultimately contributing to improvements in patient outcomes and quality of life. Looking ahead, it seeks to highlight the latest advances with the potential to expand the possibilities for retinal disease treatment, with the ultimate goal of making a meaningful contribution to the fight against vision loss.

Prof. Dr. Hisanori Imai
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vitreoretinal disorder
  • vitrectomy
  • digital assisted vitrectomy
  • intraoperative optical coherence tomography
  • diabetic retinopathy
  • epiretinal membrane

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 455 KB  
Article
Short-Term Efficacy of Two-Step Treatment of Retinopathy of Prematurity in a Japanese Cohort: Anti-VEGF Therapy Followed by Routine Laser Photocoagulation
by Shimpei Oba, Tatsunori Kiriishi, Masatoshi Omi, Yuki Hattori, Hidetsugu Mori, Masayuki Ohnaka, Takeshi Hoshino, Haruhiko Yamada and Hisanori Imai
J. Clin. Med. 2025, 14(19), 7094; https://doi.org/10.3390/jcm14197094 - 8 Oct 2025
Viewed by 447
Abstract
Objective: The aim of this study was to assess the efficacy of laser photocoagulation (LPC) combined with anti-vascular endothelial growth factor (VEGF), in comparison with routine LPC monotherapy, in the treatment of retinopathy of prematurity (ROP). Methods: This retrospective study included [...] Read more.
Objective: The aim of this study was to assess the efficacy of laser photocoagulation (LPC) combined with anti-vascular endothelial growth factor (VEGF), in comparison with routine LPC monotherapy, in the treatment of retinopathy of prematurity (ROP). Methods: This retrospective study included data from 142 eyes treated according to the standard criteria of the Early Treatment for Retinopathy of Prematurity (ETROP). Group A patients had received LPC alone, and Group B had received anti-VEGF therapy followed by routine LPC. Group B was further categorized into two subgroups: Groups B1 and B2 had received bevacizumab and ranibizumab, respectively. Data collected included ROP stage, gestational week, postmenstrual week, birth weight, number of laser spots and sessions. Results: Group B required significantly fewer laser spots than was the case with Group A (Group A: 583.0 ± 350.72, Group B: 274.9 ± 124.77, p < 0.0001). The number of LPC sessions differed significantly between the groups (Group A: 1.8 ± 1.28, Group B: 1.2 ± 0.45, p = 0.0003). Conclusions: Combining anti-VEGF therapy with routine LPC reduced the number of laser spots required. This approach offers an effective treatment strategy for managing severe ROP, potentially reducing long-term complications associated with extensive laser use. Full article
(This article belongs to the Special Issue Retinal Diseases: Emerging Therapies and Vision Rehabilitation)
Show Figures

Figure 1

Back to TopTop